Plain-English translation of NCT05395195 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 3 โ Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a medication already used safely in newborns to treat anemia, can also protect and repair the brain when a newborn doesn't get enough oxygen during birth. The medication works by reducing inflammation and damage in the brain, and early studies suggest it may reduce the chance of death or long-term disability. Researchers are conducting this large study in low and middle-income countries where the need is greatest.
Many newborns in low-income countries suffer severe brain injury from lack of oxygen during birth, and current cooling treatments have not been shown to help in these settings. This trial exists to test whether this medication could offer a new way to protect babies' brains and improve their chances of healthy development.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If your baby is enrolled, they will receive a series of 9 injections of the medication (or placebo) given intravenously or under the skin over 9 days, starting within 6 hours of birth. Your family will need to stay in close contact with the hospital during this time and return for a follow-up assessment at 18 months to check how your baby is developing. The trial uses a 'blinded' design, meaning you won't know whether your baby receives the active medication or a placebo, but researchers will monitor your baby's safety throughout.
AI-generated summary from trial data ยท Aug 24, 2026 ยท Not medical advice
Bangladesh
India